Quetiapine in Nine Youths with Autistic Disorder
- 1 June 2004
- journal article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 14 (2) , 287-294
Abstract
The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ("much" or "very much improved" on the Clinical Global Impressions-Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.Keywords
This publication has 17 references indexed in Scilit:
- Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine FumarateThe Journal of Clinical Psychiatry, 2000
- Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic DisorderJournal of Child and Adolescent Psychopharmacology, 1999
- An Open Trial of Risperidone in Young Autistic ChildrenJournal of the American Academy of Child & Adolescent Psychiatry, 1998
- Child and Adolescent Bipolar Disorder: A Review of the Past 10 YearsJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label StudyJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- Case Study: Risperidone Treatment of Children and Adolescents with Developmental DisordersJournal of the American Academy of Child & Adolescent Psychiatry, 1996
- Use of Risperidone in Pervasive Developmental Disorders: A Case SeriesJournal of Child and Adolescent Psychopharmacology, 1996
- Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptomsAmerican Journal of Psychiatry, 1984
- A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic childrenJournal of Autism and Developmental Disorders, 1973
- Comparison of Haloperidol and Fluphenazine in Disturbed ChildrenAmerican Journal of Psychiatry, 1970